Secukinumab, a human monoclonal antibody that directly inhibits IL-17A, has shown efficacy in treating immune-mediated inflammatory diseases such as psoriasis (7,12), ankylosing spondylitis (AS) (13-, 15), and rheumatoid arthritis (RA) (16-, 18). Here, IL17A is linked to rheumatoid arthritis.